RinetERKib 是口服有效的Raf和ERK1/2的抑制剂，与 KRas-突变型非小细胞肺癌、BRaf-突变型非小细胞肺癌、KRas-突变型胰腺癌、KRas -突变型结肠癌和 KRas-突变型卵巢癌尤为相关。

Rineterkib is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.

ERK-IN-1 (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice.

1715025-32-3

C26H27BrF3N5O2

578.42

ERK-IN-1

DMSO:60 mg/ml (103.73 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years